Stay updated on Venetoclax and Azacitidine in AML Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Venetoclax and Azacitidine in AML Post-Transplant Clinical Trial page.

Latest updates to the Venetoclax and Azacitidine in AML Post-Transplant Clinical Trial page
- Check5 days agoChange DetectedNew revision entry v3.3.3 was added to the history, and HHS Vulnerability Disclosure and revision v3.3.2 were removed in the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded a new page revision entry labeled v3.3.2 and removed the previous v3.2.0 from the history, reflecting internal versioning updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRemoved the government funding/operating status banner from the page header of the NCT04128501 record. The notice previously appeared at the top of the ClinicalTrials.gov record.SummaryDifference0.5%

- Check55 days agoChange DetectedNew screenshot shows a minor UI/layout update to the Record History page without altering the listed study data or version history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check76 days agoChange DetectedUpdate: Added October 2025 study status entries and date, removed April 2025 status.SummaryDifference1%

- Check84 days agoChange DetectedCore page content updated to include a funding-status notice and operating-status guidance, plus a version upgrade from v3.1.0 to v3.2.0.SummaryDifference11%

Stay in the know with updates to Venetoclax and Azacitidine in AML Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax and Azacitidine in AML Post-Transplant Clinical Trial page.